文献速递毛发、甲与色素性疾病

外用非那雄胺喷雾治疗男性雄激素性脱发的III期随机对照试验

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-10-25

这项III期随机双盲双模拟平行组研究在欧洲45个中心纳入458例成年男性雄激素性脱发患者,评估外用非那雄胺喷雾与安慰剂的疗效和安全性,并与口服非那雄胺进行系统暴露比较。结果显示,外用非那雄胺在24周时目标区域毛发计数改善显著优于安慰剂,与口服非那雄胺数值相似,且系统暴露和血清DHT降低幅度明显更低。

要点

  • 外用非那雄胺24周目标区域毛发计数改善显著优于安慰剂(20.2 vs 6.7根,P<0.001)。
  • 外用非那雄胺疗效与口服非那雄胺数值相似,但系统暴露和血清DHT降低更少。
  • 外用非那雄胺耐受性良好,不良事件发生率与安慰剂无显著差异。

核心结论

  • 外用非那雄胺喷雾可显著改善男性雄激素性脱发患者的毛发计数,疗效与口服非那雄胺相似,但系统暴露和血清DHT降低幅度明显更低。

研究设计与样本

  • 随机、双盲、双模拟、平行组、24周研究,在欧洲45个中心纳入458例成年男性雄激素性脱发门诊患者。
  • 323例完成研究,446例纳入安全性评估。

主要发现

  • 第24周目标区域毛发计数较基线变化,外用非那雄胺显著优于安慰剂(校正平均变化20.2 vs 6.7根,P<0.001),与口服非那雄胺数值相似。
  • 第12周目标区域毛发计数较基线变化及第24周研究者评估的患者毛发增长/脱落变化,外用非那雄胺均显著优于安慰剂。
  • 外用非那雄胺与安慰剂在不良事件发生率和类型及停药原因方面无有意义的差异,无治疗相关严重不良事件。
  • 外用非那雄胺的血浆峰浓度比口服低>100倍,血清DHT平均浓度较基线降低幅度更低(34.5% vs 55.6%)。

临床怎么用

  • 外用非那雄胺喷雾可作为男性雄激素性脱发的治疗选择,尤其适用于关注系统暴露或口服治疗耐受性问题的患者。

局限性

  • 研究为期24周,长期疗效和安全性未报告。
  • 研究仅纳入成年男性雄激素性脱发患者,结果不适用于女性或其它类型脱发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral finasteride is a well-established treatment for men with androgenetic alopecia (AGA), but long-term therapy is not always acceptable to patients. A topical finasteride formulation has been developed to minimize systemic exposure by acting specifically on hair follicles. OBJECTIVES: To evaluate the efficacy and safety of topical finasteride compared with placebo, and to analyse systemic exposure and overall benefit compared with oral finasteride. METHODS: This randomized, double-blind, double dummy, parallel-group, 24-week study was conducted in adult male outpatients with AGA at 45 sites in Europe. Efficacy and safety were evaluated. Finasteride, testosterone and dihydrotestosterone (DHT) concentrations were measured. RESULTS: Of 458 randomized patients, 323 completed the study and 446 were evaluated for safety. Change from baseline in target area hair count (TAHC) at week 24 (primary efficacy endpoint) was significantly greater with topical finasteride than placebo (adjusted mean change 20.2 vs. 6.7 hairs; P < 0.001), and numerically similar between topical and oral finasteride. Statistically significant differences favouring topical finasteride over placebo were observed for change from baseline in TAHC at week 12 and investigator-assessed change from baseline in patient hair growth/loss at week 24. Incidence and type of adverse events, and cause of discontinuation, did not differ meaningfully between topical finasteride and placebo. No serious adverse events were treatment related. As maximum plasma finasteride concentrations were >100 times lower, and reduction from baseline in mean serum DHT concentration was lower (34.5 vs. 55.6%), with topical vs. oral finasteride, there is less likelihood of systemic adverse reactions of a sexual nature related to a decrease in DHT with topical finasteride. CONCLUSION: Topical finasteride significantly improves hair count compared to placebo and is well tolerated. Its effect is similar to that of oral finasteride, but with markedly lower systemic exposure and less impact on serum DHT concentrations.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2021. PMID: 34634163. doi:10.1111/jdv.17738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。